---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066924"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:35:34.211310+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q1 net loss $28.1M; cash $318.9M; BEACH301 achondroplasia study open

## Summary
- Net loss $28.1M vs $18.2M in Q1 2024; R&D expense $25.0M (up 45% YoY) driven by clinical start-up costs.
- Cash, equivalents, and marketable securities $318.9M as of March 31, 2025; runway through at least 2027.
- BEACH301 Phase 2 study of TYRA-300 for pediatric achondroplasia now enrolling safety sentinel cohort.
- SURF431 Phase 1 study of TYRA-430 (FGFR4/3 inhibitor) in HCC initiated; first patient dosed.
- SURF302 Phase 2 NMIBC study of TYRA-300 expected to dose first patient in Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-066924
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017025066924/0000950170-25-066924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017025066924/tyra-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066924
- JSON: https://secwatch.observer/filing/0000950170-25-066924.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066924.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.